

Please find attached draft announcement for "green light" to release. Please note that this will appear on the screen in continuous form, therefore, the pagination is unimportant. Please confirm your authority to release the announcement by initialling each page and returning the page(s) to us and by such authority you will confirm that you are wholly responsible for and have verified the accuracy of the contents of the announcement.

Clients should take note that under Section 118 of the Financial Services and Markets Act 2000 (which became effective on 1 December 2001), it is an offence to engage in behaviour constituting market abuse. Market abuse includes behaviour creating a false or misleading impression as to the supply of, or demand for, or price or value of investments. This offence would extend to misleading RNS announcements even if such a statement was not intended to mislead. It is also a criminal offence under Section 397 of the Act intentionally to create such a false or misleading impression for the purpose of inducing another person to deal or refrain from dealing or exercising rights in investments. If you are in any doubt as to the effect of this legislation or the contents of any announcement you should take your own legal advice.

(please initial here)

PH.

Immunodiagnostic Systems Holdings PLC  
23 February 2010

#### Exercise of Share Options and Total Voting Rights

Immunodiagnostic Systems Holdings PLC ("the Company"), a leading producer of diagnostic testing kits, announces that on 19 February 2010, 1,783 ordinary shares of 2p each in the Company (the "Ordinary Shares") were allotted in a board meeting to satisfy an exercise of options exercised under the Company's SAYE scheme. Application will be made at the earliest practicable opportunity for admission of the new ordinary shares to trading on AIM.

#### Total Voting Rights

In accordance with FSA's Disclosure and Transparency Rules, the Company advises that its increased issued share capital comprises 27,854,566 Ordinary Shares. The voting rights of all of these shares are identical with each share carrying the right to one vote. The Company holds no ordinary shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Immunodiagnostic Systems Holdings PLC under the Disclosure and Transparency Rules.

#### Contacts:

Immunodiagnostic Systems Holdings PLC Tel: 0191 519 0660  
Roger Duggan, CEO  
Paul Hailes, Finance Director

Brewin Dolphin Investment Banking Tel: 0845 213 4730

Andrew Emmott  
Sean Wyndham-Quin

Walbrook PR Ltd

Ben Knowles

Tel: 020 7933 8788

Mob: 07900 346 978